Capricor Plunges 14.84% on Mid-Cycle Review

On May 5, 2025, Capricor's stock experienced a significant drop of 14.84% in pre-market trading, reflecting a notable decline in investor sentiment.

Capricor Therapeutics recently announced the completion of its mid-cycle review, a critical milestone in its ongoing clinical trials. This development is part of the company's broader strategy to advance its therapeutic pipeline and bring innovative treatments to market.

Additionally, Capricor reported its Q3 2024 earnings, posting a revenue of $2.3 million. While this figure may not be groundbreaking, it underscores the company's efforts to generate revenue through its existing products and services, providing a foundation for future growth.